AMD Clinical Trials

43 recruitingLast updated: May 21, 2026

There are 43 actively recruiting amd clinical trials across 28 countries. Studies span Phase 2, Not Applicable, Phase 3, Phase 1, Early Phase 1, Phase 4. Top locations include Dallas, Texas, United States, Austin, Texas, United States, Sacramento, California, United States. Updated daily from ClinicalTrials.gov.


AMD Trials at a Glance

43 actively recruiting trials for amd are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Dallas, Austin, and Sacramento. Lead sponsors running amd studies include AbbVie, Adverum Biotechnologies, Inc., and Fondazione G.B. Bietti, IRCCS.

About AMD Clinical Trials

Looking for clinical trials for AMD? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new AMD trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about AMD clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 43 trials

Recruiting

Cell Collection to Study Eye Diseases

Retinal DegenerationRetinitis PigmentosaRetinal Disease+1 more
National Eye Institute (NEI)930 enrolled1 locationNCT01432847
Recruiting
Phase 3

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Age related macular degeneration (AMD)Geographic Atrophy (GA)
Regeneron Pharmaceuticals975 enrolled216 locationsNCT06541704
Recruiting
Not Applicable

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

Geographic Atrophy secondary to Age Related Macular DegenerationAge-Related Macular DegenerationIntermediate AMD+1 more
i-Lumen Scientific AUS PTY LTD100 enrolled13 locationsNCT06662162
Recruiting
Phase 3

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular DegenerationnAMD
Hoffmann-La Roche68 enrolled16 locationsNCT05562947
Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled36 locationsNCT07482176
Recruiting
Phase 3

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

wet age related macular degenerationAMDnAMD+3 more
AbbVie714 enrolled181 locationsNCT05407636
Recruiting
Phase 3

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics480 enrolled94 locationsNCT07064759
Recruiting

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
Bayer50,000 enrolled1 locationNCT07308639
Recruiting

Enhanced Vision and Imaging Tests for Enabling Treatment Trials in Early and Intermediate AMD

Age related macular degeneration (AMD)
Maximilian Pfau150 enrolled1 locationNCT07515521
Recruiting
Not Applicable

Proteomic Biomarker Identification in AMD, Diabetic Retinopathy and Retinal Detachment

Age related macular degeneration (AMD)Diabetic Retinopathy (DR)Retinal Detachment
Fondazione G.B. Bietti, IRCCS260 enrolled1 locationNCT07500324
Recruiting
Not Applicable

International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study

Age related macular degeneration (AMD)
VisionCare, Inc.44 enrolled12 locationsNCT07164378
Recruiting
Phase 3

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Innostellar Biotherapeutics Co.,Ltd332 enrolled31 locationsNCT07317934
Recruiting
Not Applicable

Active AMD Study to Improve Function in Veterans

Age related macular degeneration (AMD)
VA Office of Research and Development70 enrolled1 locationNCT05932069
Recruiting

EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).

Age related macular degeneration (AMD)
Insel Gruppe AG, University Hospital Bern50 enrolled1 locationNCT07434713
Recruiting

Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages

AMD - Age-Related Macular Degeneration
Marco Mazzola60 enrolled1 locationNCT07427160
Recruiting
Phase 2Phase 3

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

AMDnAMD
AbbVie630 enrolled89 locationsNCT04704921
Recruiting
Not Applicable

Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

Age-Related Macular DegenerationAMD
VisionCare, Inc.76 enrolled13 locationsNCT04796545
Recruiting
Phase 1

A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

AMD - Age-Related Macular DegenerationAge-related Macular Degeneration (ARMD)
Aptabio Therapeutics, Inc.68 enrolled1 locationNCT07330674
Recruiting
Phase 2

Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy

Age related macular degeneration (AMD)
Assistance Publique - Hôpitaux de Paris90 enrolled1 locationNCT04292080
Recruiting
Phase 1Phase 2

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Bionic Sight LLC40 enrolled1 locationNCT07158775